Dr. Petra Hamerlik is the Chair of Translational Neuro-Oncology at the University of Manchester. She previously served as Principal Scientist and CNS Cancer Bioscience Lead at AstraZeneca, where she ...

Epitopea, a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies, today announced the formation of its dedicated clinical team and the ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the appointment of Linda Jónsdóttir as ...

Chicago-based physician to contribute through Anosh Inc Foundation and host local fundraiser in support of federal agents ...

The Anosh Foundation is a nonprofit organization dedicated to advancing ethical and accessible healthcare worldwide. Founded ...

SugarTop Buddery is known for its music and artist collaborations, stylish pre-rolls, and emphasis on social equity and women ...

The Tecan Group (SIX Swiss Exchange: TECN) today announced a planned CEO transition, marking a new chapter in the company’s successful growth story. After nearly 12 years with Tecan, including 6 ½ ...

ExpertCare featured in Innovate UK Research Project ...

About the Setrusumab Phase 3 Program Ultragenyx is developing setrusumab in pediatric and young adult patients across OI sub-types I, III and IV with two late-stage studies: the pivotal Phase 2/3 ...

The Inducement Grants have been granted pursuant to the Company’s 2023 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into ...

Ladenburg Thalmann & Co, Inc. is acting as the exclusive placement agent for the offering.

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) (“Rhythm”), a global, commercial-stage biopharmaceutical company dedicated to transforming the lives of patients living with rare neuroendocrine diseases, ...